Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After Treatment With Basal Insulin

Inclusion Criteria: * Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.) * Female or male, 18 years≤age≤70years * Subjects with insulin naïve type 2 diabetes who have been treated with metformin（\>1g/d）alone for at least 3 months prior to screening * 11%≥HbA1c≥7.5% based on analysis from a central laboratory * 24kg/m2≤BMI≤40kg/m2 * Weight fluctuation\<2kg in one month prior to screening * Able and willing to perform self-monitoring of blood glucose. * Willing to accept basal insulin therapy * Able to self-inject all required doses of insulin Exclusion Criteria: * Treatment with any OADs (Oral Antidiabetic Drugs) in the last 6 months, except metformin (subjects currently treated with metformin within the interval of 1000-2000 mg daily may be included in the trial. The dose should have remained unchanged for a period of one month prior to randomisation and should be expected to remain unchanged throughout the trial period). * Use of approved weight lowering pharmacotherapy (e.g. orlistat, sibutramine, rimonabant) or obesity induced by drug treatment (e.g. corticosteroids, NSAIDs, tricyclic anti-depressants, atypical anti-psychotics). * Participation in a clinical study of weight control within the last 3 months prior to screening. * Previous or planned surgical treatment of obesity. * Any disease or condition (such as renal, hepatic or cardiac) according to the judgment of the Investigator makes the subject unsuitable for participation in the trial. * Anticipated change in concomitant medication known to interfere with glucose metabolism, such as systemic steroids, non-selective beta-blockers or mono amine oxidase (MAO) inhibitors. * Anticipated change in concomitant medication known to interfere with lipid metabolism, such as lipid-lowering drugs. * Proliferative retinopathy or maculopathy that has required acute treatment within the last six months. * Uncontrolled hypertension (treated or untreated) as judged by the Investigator * Known or suspected allergy to trial product(s) or related products. * Previous participation in this trial. Participation is defined as screened. * Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures. Adequate contraceptive measures are sterilisation, intrauterine device (IUD), oral contraceptives or consistent use of barrier methods. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * Any condition that the Investigator feels would interfere with trial participation or evaluation of results. * Receipt of any investigational drug (NPH or insulin detemir) within 1 month prior to this trial. * Cardiac disease defined according to NYHA class III or IV, unstable angina pectoris and/or myocardial infarction within the last 6 months previous to the selection. * History of hypoglycaemic unawareness. * With mental implant (such as cardiac pacemaker, insulin pump) in vivo.